Home
overview

SMi's Superbugs & Superdrugs Conference is now in it's 13th year.

Visit the 2011 event page

 


 
2006 Past Event Details:

In 2004 the global antibacterial market was valued at approximately $24 billion. Despite this major antibacterial players have faced significant hurdles in terms of increasing and maintaining their product revenue. 2005 has brought renewed investment to the area with the acquisition of Vicuron’s dalbavancin and Johnson and Johnson’s investment in doripenem and ceftobipole. With a renewed commitment to combating serious hospital infections and other virulent strains of infectious disease there is hope for this previously neglected sector

SMi’s 8th Annual conference on Superbug & Superdrugs: A Focus on Antimicrobials aims to uncover the latest clinical and commercial factors affecting the decision of key industry players in the antibacterials market. Consideration will be given to the regulatory implications and how these bodies can facilitate more efficient antibacterial development. By exploring major drug classes we will hear discussion on new and novel advances, the impact of resistance and promising new drug classes for the community-based market. Learn what big pharma are doing to fight back, including an exploration into their role in revitalising activity and prescence, in-house research and development strategies and current and future pipeline activity. Finally this conference will consider the increasing role of resistance and its impact on antibacterial, antifungal and antiviral drug development.

This is a must attend event for all those involved in the anti-infectives market!

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hear contributions from leading industry experts, including:

 

  • Dr David Pompliano, Vice President, Biology, Microbial Musculoskeletal & Proliferative Diseases Centre for Excellence in Drug Discovery, GlaxoSmithKline
  • Dr Evelyn Ellis-Grosse, Assistant Vice President,  Wyeth Research
  • Dr Richard Bax, Vice President, European Medical Group, Chiron Corporation
  • Dr Kenneth Tack, Executive Director, Pfizer
  • Dr Yat Sun Or, Senior Vice President, Research & Development, Enanta Pharmaceuticals
  • Dr Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene
  • Dr David Payne, Director, Microbiology, GlaxoSmithKline
  • Professor Malcolm Page, Head, Biology, Basilea Pharmaceutica
  • Dr Wright Nichols, Director, Microbiology, AstraZeneca

 

Note from the Chair:

‘The need for new antibiotics remains as critical as ever and the spotlight is on those companies invested in this important therapeutic area. Furthermore, antibacterial R&D is proving to be a very challenging endeavour and proven experts from the key biotechs and big pharma remaining in the field will discuss their strategies and highlight new advances.’

Dr David Payne, Director, Microbiology, GlaxoSmithKline

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

David Payne

David Payne, Director, Microbiology, GlaxoSmithKline

9:10 KEYNOTE ADDRESS

Richard Bax

Richard Bax, Vice President, European Medical Group, Chiron Corporation

  • The story so far: fate of companies presentations to superbugs and superdrugs 1999, 2000 and 2001
  • Where are they now?
  • What have they produced?
  • What is the likely impact of mergers and acquisitions?
  • Availability of finance, increase in cost and complexity of licensing as well as increases in post-approval commitments?
  • What is in the development pipEline now?
  • 2006-2010 and beyond
  • 9:50 OVERCOMING CHALLENGES IN THE ANTI-INFECTIVES MARKET

    Wright Nichols

    Wright Nichols, Director, Micobiology, AstraZeneca R&D Boston

  • Can the industry keep up with the bacterial evolution?
  • What role do pharmaceutical discovery play?
  • Rising to the challenge – improvements in target-based drug discovery
  • What are the current issues in hit to lead?
  • Finding hits
  • Overcoming problems in antimicrobial R&D
  • Is there still a focus on infectious disease?
  • 10:30 Morning Coffee

    10:50 NEW MACROLIDES ACTIVE AGAINST MRSA

    Yat Sun Or

    Yat Sun Or, Senior Vice President, Research & Development, Enanta

  • The emergence of methecillin-resistant S. aureus (MRSA) and vancomycin resistant Entorococcus (VRE)
  • Innovative macrolide structural modifications
  • A new class of macrolides active against Strep and Straphyl resistance, including MRSA
  • Structure-activity relationship of Enanta’s new macrolides
  • Future in macrolide antibacterial drug discovery research
  • 11:30 PEPTIDE DEFORMYLASE INHIBITORS

    Simon Bushell

    Simon Bushell, Research Investigator, Global Discovery Chemistry, Novartis

  • Targeting an enzyme essential for bacterial cell growth – a novel mode of action
  • Design and development of peptide deformylase inhibitors (PDFi’s)
  • Identification of additional lead candidates – does this validate a mechanism-based drug design approach?
  • Moving forward towards the clinic with PDFi’s
  • 12:10 IDENTIFICATION OF AN ATP SYNTHASES INHIBITOR AS A NOVEL DRUG CANDIDATE FOR THE TREATMENT OF TUBERCULOSIS

    Anil Koul

    Anil Koul, Principal Scientist, Johnson & Johnson

  • No new TB compound has been developed for the last 40 years in spite of 2 million deaths each year
  • Identification of a novel drug class, Diarylquinolines, as wonder candidates for TB treatment
  • This class has shown activity on Multi-Drug Resistant TB (MDR-TB) and latent TB
  • Identification and validation of ATP synthases as new and novel targets for TB treatment
  • The excellent mouse and human pharmacokinetic profile of the lead candidate, R207910, explains the high potency of the drug in mice models
  • 12:50 Networking Lunch

    14:20 Rx-01 FAMILY OF DESIGNER OXAZOLIDINONES

  • Ribosome as an antibacterial target
  • Genesis of Rx-01 programme
  • Mechanism of action
  • Rx-01 Profile
  • Joyce Sutcliffe

    Joyce Sutcliffe, Vice President, Biochemistry and Molecular Biology, Rib-X Pharmaceuticals

    Joseph DeVito

    Joseph DeVito, Senior Research Fellow, Rib-X Pharmaceuticals Inc

    15:00 ANTI-INFECTIVE DRUG DISCOVERY

    David Pompliano

    David Pompliano, Vice PResident, Biology, Microbial Musculoskeletal & Proliferative Diseases Centre for Excellence in Drug Discovery, GlaxoSmithKline

  • What are the challenges of antibacterial drug discovery?
  • Why is it so difficult?
  • Is GSK giving up on antibacterials?
  • How have genomics affected antibacterial drug discovery at GSK?
  • An insight into GSK’s research and development strategies
  • Current and future pipeline activity
  • 15:40 Afternoon Tea

    16:00 Presentation details to be confirmed

    George Drusano

    George Drusano, Co-Director & Senior staff Scientist, Ordway Research Institute

    16:40 PLECTASIN - A NEW ANTIBIOTIC COMPOUND WITH SYSTEMIC ACTIVITY

    Søren Kjaerulff

    Søren Kjaerulff, Director, Novozymes

  • First microbial defensin
  • Potent activity against resistant Gram positive bacteria
  • New class of antibiotic
  • Novel mode of action
  • Production at commercial relevant scale
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Richard Bax

    Richard Bax, Vice President, European Medical Group, Chiron Corporation

    9:10 USING PK/PD IN ANTIMICROBIAL DRUG DEVELOPMENT

    Johan Mouton

    Johan Mouton, Consultant Microbiologist, Canisius Whilhelmina Hospital

  • Translating preclinical data into predictions of human outcomes
  • Lab to phase II trial: use of microbiology, animal model data and phase data for dose selection of antibiotics
  • Shaping regulatory and development decisions at the end of phase II
  • Innovative strategies for evaluating antimicrobial regimens
  • Risk assessment, management and commercialisation
  • Have PK/PD concepts really been incorporated in the most recent development of antibiotics?
  • Pharmacokinetics and pharmacodynamics in the process of drug registration
  • 9:50 CREATING AND PROGRESSING A PORTFOLIO OF NOVEL ANTIBACTERIALS

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Research, Prolysis

  • Developing an effective antibacterial discovery engine
  • Discovery and optimisation of novel inhibitors of bacterial cell division that target FtsZ
  • Profile of a novel series of broad-spectrum dual-targeting DNA supercoiling inhibitors
  • 10:30 Morning Coffee

    11:00 CHALLENGES AND SOLUTIONS OF CONDUCTING GCP TRIALS IN SUB-SAHARA AFRICA

    Josephine Hudson

    Josephine Hudson, International Project Director, MDS Pharma Services

  • Overview of a current trial in Malaria
  • Clinical trial setting in Sub-Sahara
  • Logistics, challenges and solutions
  • Application of experience gained for future GCP trials in this region
  • 11:40 CEFTOBIPROLE (BAL5788) – A CASE STUDY

    Malcolm Page

    Malcolm Page, Head, Biology, Basilea Pharmaceutica Ltd

  • Understanding the mechanism of action against MRSA and penicillin-resistant pneumococci
  • A broad-spectrum profile – activity against Gram-negative pathogens
  • Molecular basis for low development of resistance
  • Performance in animal models and clinical trials
  • 12:20 Networking Lunch

    13:50 DALBAVANCIN – A NOVEL SECOND-GENERATION GLYCOPEPTIDE AGENT

    Kenneth Tack

    Kenneth Tack, Executive Director, Pfizer Global Research & Development

  • Understanding this important new medicine
  • Mechanism of action
  • In vitro studies – a potent drug against Gram-positive bacteria
  • Activity in animal models of infection
  • Pharmacokinetics
  • Results of clinical studies
  • Road to approval – how long before this drug reaches the market?
  • 14:30 GLYCYLCYCLINES – A NEW CLASS OF MEDICINE

  • A novel IV antibiotic with a broad spectrum of antimicrobial activity
  • Target use and possible opportunities for disease/infection control
  • A viable replacement/beneficial substitute for tetracycline?
  • Understanding the mechanism of action
  • Insight into clinical trial results
  • Discussion on in vitro data showing activity against both Gram-negative and Gram-positive bacteria, anaerobes and certain drug-resistant pathogens
  • What does the approval of Tygacil mean for the industry?
  • Evelyn Ellis-Grosse

    Evelyn Ellis-Grosse, Assistant Vice President, Wyeth Research

    15:10 Afternoon Tea

    15:40 ANTI-FUNGAL RESISTANCE AND RESISTANCE DEVELOPMENT

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, Vice President, Infectious Diseases, Methygene

  • Clinical importance and mechanisms of anti-fungal resistance
  • Understanding the selection of the inherently susceptible species
  • Candida krusei and C.glabrata are inherently less susceptible to fluconazole and other triazole compounds – why is this?
  • Acquired resistance in previously susceptible species
  • What differences are there between the problems of anti-fungal resistance and those of antibacterial resistance?
  • Are there over-arching mechanisms determining anti-fungal resistance?
  • 16:20 AN UPDATE ON ANTIVIRAL RESISTANCE

    John Oxford

    John Oxford, Professor, Virology & Scientific Director, The Royal London Hospital & Retroscreen Virology Ltd

  • The next pandemic – bird flu H5N1
  • What can be done to curtail the threat from human to human transmission?
  • How effective are antiviral treatments for influence against avian flu?
  • Combining prophylactic with amantadine or romantadine – what are the effects on the rate of illness?
  • M2 inhibition and resistance
  • The key to pandemic management – neurominidase inhibitors
  • Stockpiling – which drug should be chosen and in what quantity should it be stored?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Translating Innovation to Success in Antimicrobial Drug Discovery and Development
    Workshop

    Translating Innovation to Success in Antimicrobial Drug Discovery and Development

    The Grange Holborn Hotel
    26th April 2006
    London, United Kingdom

    The Grange Holborn Hotel

    50-60 Southampton Row
    London WC1B 4AR
    United Kingdom

    The Grange Holborn Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.